Payment overview · 2025
General Payments
$989.35
47 reported records · 18 companies
Healthcare provider profile · identity verified
Marc Vanderleeden, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · SPRINGFIELD, MA · NPI 1801883194
Verified facts
What the public records show
CMS Open Payments records show Marc Vanderleeden, M.D. received $989.35 in general payments during 2025 across 47 reported records.
Novo Nordisk Inc accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Mycapssa.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Jardiance by this doctor in 2024.
Chiesi USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MYCAPSSA as an associated drug or biological on 1594 records involving 919 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mycapssa by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 530 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $194.96 | 19.7% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $180.65 | 18.3% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $108.12 | 10.9% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $107.14 | 10.8% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.24 | 6.2% | 3 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $58.30 | 5.9% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.97 | 4.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $33.08 | 3.3% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $24.97 | 2.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $24.48 | 2.5% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $24.26 | 2.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.45 | 2.2% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $21.40 | 2.2% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $19.07 | 1.9% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.44 | 1.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.39 | 1.8% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $15.46 | 1.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.97 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $989.35 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $175.51 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $112.28 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $108.46 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $91.59 | 5 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $69.50 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $63.44 | 3 | 2025 |
Source payment records
|
|||||
| MYCAPSSA Normalized: mycapssa |
Drug | Chiesi USA, Inc. | $58.30 | 3 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $44.97 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $38.62 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.53 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $33.08 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| GENOTROPIN Normalized: genotropin |
Drug | PFIZER INC. | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| SOMAVERT Normalized: somavert |
Drug | PFIZER INC. | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 210 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 530 | exact normalized | Medicare Part D |
| MYCAPSSA mycapssa |
2025 | Mycapssa | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
82 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
210 | 57 |
| Chiesi USA, Inc. Exact reporting entity; no affiliate inference |
2025 | MYCAPSSA open payments reported associated product |
CMS Open Payments — General Payments 1594 supporting records · 919 recipient NPIs · example record 1242155545 |
Mycapssa · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
210 | 57 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
530 | 95 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
118 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Mounjaro | Tirzepatide | 530 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 431 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 325 | 89 |
| Jardiance | Empagliflozin | 210 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 196 | 48 |
| Glipizide | Glipizide | 164 | 42 |
| Lisinopril | Lisinopril | 151 | 42 |
| Metformin Hcl | Metformin Hcl | 148 | 50 |
| Simvastatin | Simvastatin | 148 | 39 |
| Lorazepam | Lorazepam | 147 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 122 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 37 |
| Trulicity | Dulaglutide | 118 | 28 |
| Omeprazole | Omeprazole | 111 | 35 |
| Alendronate Sodium | Alendronate Sodium | 89 | 30 |
| Gabapentin | Gabapentin | 87 | 28 |
| Sertraline Hcl | Sertraline Hcl | 85 | 25 |
| Synthroid | Levothyroxine Sodium | 82 | 22 |
| Ezetimibe | Ezetimibe | 81 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 76 | 18 |
| Tramadol Hcl | Tramadol Hcl | 74 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 73 | 23 |
| Trazodone Hcl | Trazodone Hcl | 72 | 18 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 71 | 22 |
| Farxiga | Dapagliflozin Propanediol | 68 | 22 |
| Testosterone | Testosterone | 62 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 54 | 15 |
| Irbesartan | Irbesartan | 52 | 14 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 49 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 12 |
| Losartan Potassium | Losartan Potassium | 45 | 12 |
| Eliquis | Apixaban | 42 | suppressed |
| Clonazepam | Clonazepam | 41 | suppressed |
| Hydrocortisone | Hydrocortisone | 40 | 12 |
| Potassium Chloride | Potassium Chloride | 37 | suppressed |
| Furosemide | Furosemide | 36 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Humalog | Insulin Lispro | 34 | 11 |
| Alprazolam | Alprazolam | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 29 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Mycapssa | Octreotide Acetate | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Tirosint | Levothyroxine Sodium | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Levoxyl | Levothyroxine Sodium | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $989.35 · 47 records | Novo Nordisk Inc | CRENESSITY, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, GENOTROPIN, IMCIVREE, ISTURISA, JARDIANCE, Kerendia, MOUNJARO, MYCAPSSA, Ozempic, RECORLEV, Repatha, Rybelsus, SOMAVERT, TZIELD, Tymlos, Wegovy, XYOSTED, Yorvipath, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error